Myeisha Casmire Clifton
Family · Beaumont, TXNPI 1821527284
Payments from drug & device makers
Across 318 payments — averaging $25.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$3K
- Merck$2K
- Viiv Healthcare Company$1K
- AstraZeneca$310
- Janssen Products, LP$269
- AbbVie$259
- plus $2K from 21 others
What the payments were for
- Consulting fees$6408%
- Speaking & faculty fees$1,36517%
- Travel & lodging$881%
- Food & beverage$5,72270%
- Education$3094%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 105 | $2,572 |
| Merck | 30 | $2,055 |
| Viiv Healthcare Company | 72 | $1,114 |
| AstraZeneca | 19 | $310 |
| Janssen Products, LP | 3 | $269 |
| AbbVie | 13 | $259 |
| Johnson & Johnson(2 entities) | 12 | $214 |
| Theratechnologies Inc. | 8 | $195 |
| Novo Nordisk | 11 | $180 |
| Neurocrine Biosciences, Inc. | 5 | $160 |
| EMD Serono, Inc. | 8 | $146 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $103 |
| GSK | 3 | $66 |
| Amgen | 2 | $60 |
| Lilly USA, LLC | 3 | $57 |
| Napo Pharmaceuticals Inc | 3 | $55 |
| Pfizer | 2 | $49 |
| Exact Sciences | 2 | $42 |
| Sunovion Pharmaceuticals Inc. | 2 | $42 |
| Otsuka America Pharmaceutical, Inc. | 2 | $40 |
| Teva Pharmaceuticals USA, Inc. | 2 | $35 |
| Neos Therapeutics, LP | 1 | $19 |
| Indivior Inc. | 1 | $19 |
| Vanda Pharmaceuticals Inc. | 1 | $19 |
| Alkermes, Inc. | 1 | $15 |
| Boehringer Ingelheim | 1 | $15 |
| Ironshore Pharmaceuticals Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PIFELTRO$1,481
How this compares
$8,124 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 348 | $1,346,627 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 191 | $940,479 |
| DescovyEmtricitabine/Tenofov Alafenam | 99 | $214,234 |
| CabenuvaCabotegravir/Rilpivirine | 28 | $184,137 |
| TivicayDolutegravir Sodium | 34 | $155,628 |
| OzempicSemaglutide | 65 | $79,327 |
| TrulicityDulaglutide | 52 | $71,468 |
| PifeltroDoravirine | 35 | $67,864 |
| DovatoDolutegravir Sodium/Lamivudine | 22 | $67,034 |
| SynjardyEmpagliflozin/Metformin Hcl | 65 | $59,294 |
| RybelsusSemaglutide | 32 | $55,243 |
| FarxigaDapagliflozin Propanediol | 47 | $44,741 |
| MounjaroTirzepatide | 32 | $43,831 |
| JardianceEmpagliflozin | 48 | $43,391 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 11 | $39,369 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy | $2,572 | $1,560,861447 claims |
| Janssen Products, LPSymtuza | $269 | $940,479191 claims |
| Viiv Healthcare CompanyCabenuva, Tivicay, Dovato | $1,114 | $406,80084 claims |
| Novo NordiskOzempic, Rybelsus | $180 | $134,57097 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $57 | $115,29984 claims |
| Boehringer IngelheimSynjardy, Jardiance, Combivent Respimat | $15 | $108,608124 claims |
| MerckPifeltro, Januvia | $2,055 | $80,68946 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $310 | $70,26774 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $66 | $30,94343 claims |
| PfizerEliquis | $49 | $18,53021 claims |
| AbbVieLinzess | $259 | $9,83617 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 15,456 family providers in Texas.
Other family in Beaumont
- Lashonda CraneHouston$3.4M
- David WeirDallas$959K
- Luba YammineHouston$479K
- Robin BeachHouston$428K
- Nirupama JeromeAustin$418K
- April LopezMcAllen$417K
- Linda MercadoHouston$211K
- Sarah AguilarHouston$199K
- Sie ThomasDallas$197K
- Anna CastroSan Antonio$184K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.